Repurposing Cyp51 inhibitors for Chagas disease drug discovery

Dr. Podust, an x-ray crystallographer, had been working on structure-based drug design for Chagas disease, and was interested in the potential of Cyp51 inhibitors. BVGH connected Dr. Podust with AstraZeneca, which shared 905 Cyp51 inhibitors. Dr. Podust’s collaborators, Drs. McKerrow and Siqueira-Neto, screened the compounds in high-throughput and cell-based assays against T. cruzi.